|
KMID : 0923620220220050043
|
|
Immune Network
2022 Volume.22 No. 5 p.43 ~ p.43
|
|
|
1,3-Dibenzyl-5-Fluorouracil Prevents Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Differentiation
|
|
Jeon Hyo-Eun
Yu Jung-Eun
Hwang Jung-Me
Park Hye-Won
Yu Ji-Yeon
Lee Zee-Won
Kim Tae-Soo
Rho Jae-Rang
|
|
|
Abstract
|
|
|
|
Osteoclasts (OCs) are clinically important cells that resorb bone matrix. Accelerated bone destruction by OCs is closely linked to the development of metabolic bone diseases. In this study, we screened novel chemical inhibitors targeting OC differentiation to identify drug candidates for metabolic bone diseases. We identified that 1,3-dibenzyl-5-fluorouracil, also named OCI-101, is a novel inhibitor of osteoclastogenesis. The formation of multinucleated OCs is reduced by treatment with OCI-101 in a dose-dependent manner. OCI-101 inhibited the expression of OC markers via downregulation of receptor activator of NF-κB ligand and M-CSF signaling pathways. Finally, we showed that OCI-101 prevents ovariectomy-induced bone loss by suppressing OC differentiation in mice. Hence, these results demonstrated that OCI-101 is a good drug candidate for treating metabolic bone diseases.
|
|
|
KEYWORD
|
|
|
Osteoclasts, Osteoclastogenesis, 1,3-Dibenzyl-5-fluorouracil, Ovariectomy, Osteoporosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|